BC Platforms, a world leader in genomic data management and analytics, announced that it has formed a collaboration with Blueprint Genetics, a leader in the field of clinical genetic testing, to develop new data driven services for hospitals and the life sciences industry.
The collaboration combines Blueprint Genetics‘ excellence in clinical genetic testing with BC Platforms’ high performing data management platform to facilitate the utilization of large amounts of genetic data in day-to-day patient care, clinical studies and industry initiatives such as sponsored testing programs. This all-encompassing approach will be supported by a secure and fully compliant system that maintains privacy while supporting openness and collaboration.
The second element of this project will be the creation of an advanced platform for the provision of genetic data and providing a scalable environment for data storage and analysis. This technology is supported by high-quality, curated data sets and health-related information. Such a wide breadth of organized, harmonized data will support efficient genetic testing results and ultimately improve patient care. Essentially, creating this seamless platform for integrated genetic testing and clinical data applications will serve to enable precision medicine by combining technical expertise and unique approaches to clinical genomics.
Tero Silvola, CEO of BC Platforms, commented on the partnerships, “We are delighted to be working with Blueprint Genetics, who are rapidly establishing themselves as leaders in the clinical genetic testing field for rare diseases. We believe that together we can provide a highly competitive platform and a one-stop shop for genetic testing and data management to help patients suffering from rare inherited diseases.”
“I am very excited about this collaboration. Linking our high-quality genetic testing with BC Platforms data management capabilities allows us to improve patient outcomes, reduce operating costs in healthcare organizations and speed up the time-to-discovery,” commented Blueprint Genetics’ CEO Tommi Lehtone